- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07700693
4-7-8 Breathing for Fatigue and Sleep Management in Hemodialysis
The Effect of the 4-7-8 Breathing Exercise Program on the Management of Fatigue and Sleep Disorders in Hemodialysis Patients: A Randomized Controlled Trial
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
This study was designed as a randomized controlled trial. The estimated sample size was calculated using the G*Power 3.1.9.7 software. The calculation was based on parameters from a preliminary study on the effects of breathing exercises in hemodialysis patients (Güvener & Koç, 2025). For the independent two-group t-test, an analysis was conducted assuming 95% power (1-β), a significance level of α=0.05, and a large effect size (d=0.80). As a result, it was determined that 35 participants were needed in each group, for a total of 70 participants. Taking potential dropouts into account, the study will begin with a total of 80 participants, and analyses will be conducted using data from at least 70 participants who have completed the follow-up.
Inclusion Criteria: Age between 18 and 85 years; receiving hemodialysis treatment for at least 3 months; no diagnosis of malignant respiratory disease (e.g., bronchial or lung cancer); no pathological condition affecting consciousness or focus (e.g., dialysis dementia or uremic encephalopathy); native Turkish speaker.
Exclusion Criteria: Advanced reading comprehension problems; advanced hearing impairment; presence of sleep apnea; known psychiatric illness.
Intervention Group Protocol: Participants in the experimental group will be taught a standardized program consisting solely of the 4-7-8 breathing technique. The intervention will last four weeks. The technique will be demonstrated face-to-face by a research nurse, and patients will be provided with a short instructional video that explains the technique step by step. The video will be sent to patients' smartphones to encourage them to practice independently at home.
4-7-8 Breathing Technique Instructions:
Patients will be asked to sit or lie down in a comfortable position and follow the cycle below:
4 seconds: Take a slow, deep breath in through the nose.
7 seconds: Hold the breath.
8 seconds: Exhale slowly and completely through the mouth, with lips slightly pursed (making a slight hissing sound).
This cycle will be repeated 10 times consecutively per session, with a total duration of approximately 10-15 minutes. Participants will be asked to perform the technique twice daily (once during the day and once before bedtime). To monitor adherence, patients will be given a simple practice log, and weekly reminders will be provided via phone calls or messages. On hemodialysis session days, the exercise will be performed during the HD session under the supervision of the research nurse.
Control Group Protocol: Participants in the control group will continue with their current routine hemodialysis care and will not be included in any structured breathing exercise program.
Assessment: Fatigue (Chalder Fatigue Scale), sleep quality (Jenkins Sleep Scale), and daytime sleepiness (Epworth Sleepiness Scale) will be assessed at three time points: at baseline (pre-test), at the end of the second week, and at the end of the fourth week of the intervention.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria: Age between 18 and 85 years; receiving hemodialysis treatment for at least 3 months; no diagnosis of malignant respiratory disease (e.g., bronchial or lung cancer); no pathological condition affecting consciousness or focus (e.g., dialysis dementia or uremic encephalopathy); native Turkish speaker.
Exclusion Criteria: Advanced reading comprehension problems; advanced hearing impairment; presence of sleep apnea; known psychiatric illness.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Støttende pleje
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Experimental
Arm Description:During daily practice sessions, patients will be instructed to sit or lie down in a comfortable position and begin the breathing exercise. The patient will perform the following cycle:
Number of Repetitions: This cycle will be repeated 10 times consecutively per session, with a total duration of approximately 10-15 minutes. Participants will be asked to perform this routine twice daily (once during the day and once before bedtime) throughout the four-week intervention period. On hemodialysis session days, the exercise will be performed under the supervision of the research nurse to ensure adherence. |
A non-pharmacological behavioral intervention utilizing the 4-7-8 breathing technique.
Prior to the first session, a research nurse provides brief face-to-face training and an instructional video sent to participants' smartphones for home practice.
During daily practice sessions in a comfortable position, the cycle is performed: inhale for 4 seconds, hold for 7, exhale for 8 through pursed lips.
This 10-cycle sequence lasts approximately 10-15 minutes per session.
Applied twice daily (once during the day and once before bedtime) for four weeks, with fatigue, sleep quality, and daytime sleepiness assessed via validated questionnaires (Chalder Fatigue Scale, Jenkins Sleep Scale, Epworth Sleepiness Scale) at baseline, week 2, and week 4.
The intervention aims to reduce fatigue and sleep disturbances by activating the parasympathetic system, promoting relaxation, decreasing anxiety, and modulating autonomic balance.
|
|
Ingen indgriben: Control
Control Arm Description: Participants in the control group, on the other hand, will
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Fatigue Level
Tidsramme: Baseline, Week 2, Week 4
|
Fatigue severity experienced by the patient over the past month.
This primary outcome is measured at baseline (pre-test), at the end of the second week, and at the end of the fourth week of the intervention.
Fatigue is measured using the Chalder Fatigue Scale (CFS), an 11-item self-report scale.
The first 7 items assess physical fatigue and the last 4 items assess cognitive fatigue.
Each item is scored on a 4-point Likert scale (0-3), with total scores ranging from 0 to 33.
Higher scores indicate greater fatigue severity.
The patient completes the scale independently, and the total score is recorded.
|
Baseline, Week 2, Week 4
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Sleep Quality
Tidsramme: Baseline, Week 2, Week 4
|
Sleep quality experienced by the patient over the past week.
This secondary outcome is measured at baseline (pre-test), at the end of the second week, and at the end of the fourth week of the intervention.
Sleep quality is measured using the Jenkins Sleep Scale (JSS), a 4-item self-report scale.
Each item assesses the frequency of specific sleep problems on a 0-5 scale, with total scores ranging from 0 to 20.
Higher scores indicate poorer sleep quality.
The patient completes the scale independently, and the total score is recorded.
|
Baseline, Week 2, Week 4
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Sygdomme i nervesystemet
- Psykiske lidelser
- Patologiske processer
- Mandlige urogenitale sygdomme
- Nyresygdomme
- Urologiske sygdomme
- Urogenitale sygdomme hos kvinder
- Kvinders urogenitale sygdomme og graviditetskomplikationer
- Kronisk sygdom
- Sygdomsegenskaber
- Søvnvågningsforstyrrelser
- Nyreinsufficiens
- Søvnforstyrrelser, iboende
- Dyssomnier
- Patologiske tilstande, tegn og symptomer
- Søvninitiering og vedligeholdelsesforstyrrelser
- Nyreinsufficiens, kronisk
- Undersøgelsesteknikker
- Metoder
Andre undersøgelses-id-numre
- 21.01.2026/2761
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Kroniske nyresygdomme
-
Zhen LiTilmelding efter invitationSamtidig pancreas-Kidney-transplantationKina
-
Chung Shan Medical UniversityNational Science and Technology Council, TaiwanAfsluttetFedme type 2 diabetes mellitus | Metabolisk dysfunktion-associeret steatotisk leversygdom | Kardiovaskulær-Kidney-metabolsk syndromTaiwan
-
University Hospital, Basel, SwitzerlandIkke rekrutterer endnuKardiovaskulær-Kidney-metabolsk syndrom | Cradiovascular-Kidney-Liver-Metabolic (CKLM) syndromSchweiz
-
CHU de ReimsIkke rekrutterer endnuFluid reaktionsevne i tidlig transplantationsperiode efter KidneyFrankrig
-
Jules Bordet InstituteMacopharma; Belgian Hematological SocietyRekrutteringRefractory Chronic Graft Versus Host Disease (cGVHD)Belgien
-
Camille N. Kotton, MDKamada, Ltd.; University of Texas Southwestern Medical CenterRekrutteringCytomegalovirus | Nyretransplantation; Komplikationer | Organtransplantation | Levertransplantationskomplikationer | Samtidig lever-Kidney-transplantation; KomplikationerForenede Stater
-
Changhai HospitalRui Therapeutics Co., LtdRekrutteringRelapseret/Refraktær Immun Nefropati | Relapsed/Refractory Immune-mediated Kidney DiseaseKina
-
Nanjing Medical UniversityIkke rekrutterer endnuKardiovaskulær-Kidney-metabolsk syndrom
-
Bahria UniversityIslamabad Medical and Dental CollegeAktiv, ikke rekrutterendeAlveolær knogletab Associated Chronic PeriodontitisPakistan
-
West China HospitalIkke rekrutterer endnuPTLD'er | CAEBV (Chronic Active Epstein-Barr Virus Infection) SyndromKina
Kliniske forsøg med Intervention
-
Biolux Research Holdings, Inc.AfsluttetOrtodontisk tandbevægelseCanada
-
University of FloridaAfsluttetFølsomhedForenede Stater
-
Roswell Park Cancer InstituteAfsluttetFedme | Overvægtig | Anatomisk fase I brystkræft AJCC v8 | Anatomisk fase IA brystkræft AJCC v8 | Anatomisk fase IB brystkræft AJCC v8 | Anatomisk fase II brystkræft AJCC v8 | Anatomisk fase IIA brystkræft AJCC v8 | Anatomisk fase IIB brystkræft AJCC v8 | Anatomisk fase III brystkræft AJCC v8 | Anatomisk fase... og andre forholdForenede Stater
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RekrutteringBiokemisk tilbagevendende prostatakarcinom | Fase IV prostatakræft AJCC v8 | Stage IVA prostatakræft AJCC v8 | Stadie IVB prostatakræft AJCC v8 | Metastatisk prostataadenokarcinomForenede Stater
-
University of WashingtonNational Cancer Institute (NCI)AfsluttetAvanceret malignt neoplasmaForenede Stater
-
Universidad de ExtremaduraDiputación Provincial de BadajozRekrutteringSundhedsuddannelse | Gamification in Health EducationSpanien
-
Case Western Reserve UniversityAktiv, ikke rekrutterende
-
Ohio State University Comprehensive Cancer CenterAfsluttetOndartet fast neoplasma | Neoplasma i hæmatopoietisk og lymfesystemForenede Stater
-
Fred Hutchinson Cancer CenterPrevent Cancer FoundationAfsluttet
-
M.D. Anderson Cancer CenterTrukket tilbageStadie IB3 Livmoderhalskræft FIGO 2018 | Fase II Livmoderhalskræft FIGO 2018 | Fase IIA Livmoderhalskræft FIGO 2018 | Fase IIA1 Livmoderhalskræft FIGO 2018 | Fase IIA2 Livmoderhalskræft FIGO 2018 | Stadie IIB Livmoderhalskræft FIGO 2018 | Stadie III livmoderhalskræft FIGO 2018 | Fase IIIA Livmoderhalskræft... og andre forhold